27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Controlling for baseline differences, treatment of OSA improved delayed recall and may reduce the slope of memory decline in Alzheimer’s disease and vascular dementia. 3 key findings →
Design: cohort study Participants: 86 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The ability to decode others’ emotions from multisensory cues is central to social functioning. 3 key findings →
Design: systematic review Participants: 1,511 Evidence: high
Full summary, score breakdown and related studies → Original source
This nationwide study provides epidemiological data on dementia and MCI among adults aged ≥ 60 years across all 12 administrative regions of Morocco. 1 key finding →
Design: cross-sectional Participants: 1,662 Evidence: low
Full summary, score breakdown and related studies → Original source
Detection and characterisation of dementia and Mild Cognitive Impairment (MCI) is essential for diagnosis and to support recruitment of patients into trials of disease-targeted therapies. 1 key finding →
Participants: 46 Evidence: low
Full summary, score breakdown and related studies → Original source
Structured Abstract Background Alzheimer’s disease (AD) neuropathology emerges decades before symptoms, requiring sensitive, non-invasive markers for early diagnosis. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
To distinguish these cases, we trained three types of supervised 3D transformers (ViT3D, MINiT, NIT) and, as a non-collapsing alternative, a frozen self-supervised encoder (DINO), to classify people with dementia or mild cognitive impairment (MCI) versus cognitively normal (CN) individuals from 3D brain MRI, using data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Subcortical brain alterations are a key feature of dementia disease progression. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Spontaneous speech acoustics capture p-tau217/APOE-defined AD risk despite preserved cognition, supporting speech as a scalable, biologically grounded biomarker for preclinical AD risk stratification. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid plaques contain numerous proteins in addition to amyloid beta in Alzheimer’s disease (AD). 4 key findings →
Participants: 240 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 10,489 participants with incident MCI, the mean age at the incident MCI wave was 70.6 years (SD = 11.53), and 56.6% were female. 5 key findings →
Design: cohort study Participants: 10,489 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Approximately 90% of Parkinson's disease (PD) patients exhibit olfactory deficits, which often precedes motor symptoms by years, and are a robust predictor for PD and subsequent cognitive decline. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Isolated rapid eye movement sleep behaviour disorder (iRBD) strongly predicts future Lewy body disease and identifies a more aggressive, non-motor phenotype in Parkinson’s disease (PD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Parkinson’s disease (PD) exhibits considerable variability in symptom onset, severity, and clinical trajectories, making prediction of individual disease progression a complex challenge. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Older adults with mild cognitive impairment (MCI) or dementia have elevated fall risk, but fall-related psychological outcomes represent distinct constructs that should not be pooled indiscriminately. 5 key findings →
Participants: 327 Evidence: high
Full summary, score breakdown and related studies → Original source
Performance variability precedes measurable linear decline across PD-risk stratified groups. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Fairness in clinical machine-learning (ML) remains a critical challenge, particularly in neurodegenerative disease where demographic factors may confound disease-related patterns. 1 key finding →
Participants: 757 Evidence: low
Full summary, score breakdown and related studies → Original source
In this cross-sectional sample, mobility showed a progressively stronger statistical indirect association with the cognition-ADL relationship as cognitive impairment deepened. 3 key findings →
Design: cross-sectional Participants: 1,234 Evidence: moderate
Full summary, score breakdown and related studies → Original source
PTGDS followed a biphasic astrocytic trajectory with a statistically resolved donor-level inflection (quadratic term −2.27, p = 0.006; vertex at pseudo-progression score 0.47, bootstrap 95% confidence interval 0.32 to 0.53). 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Insulin resistance is increasingly recognized as a metabolic factor associated with Alzheimer’s disease (AD); however, its relevance to hippocampal structural changes—a key pathological feature of AD—across disease stages is not fully understood. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In dialect-dominant, educationally diverse elderly, Mini-cog provides superior diagnostic accuracy for MCI versus HKBC and MoCA, and comparable accuracy for dementia. 4 key findings →
Design: cross-sectional Participants: 450 Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 2,090 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →